VolitionRX Stock

VolitionRX EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of VolitionRX (VNRX) as of Aug 10, 2026 is -287.52 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -128.76 % — a change of 123.30% (lower).

EBIT/Assets

-287.52 %

YoY

123.30%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of VolitionRX is 2026 -287.52 % . Operating Income to Assets Ratio (EBIT/Assets) of VolitionRX was 2025 -128.76 % . It decreases by 123.30% lower compared to the previous year.
Access this data via the Eulerpool API

VolitionRX Stock analysis

What does VolitionRX do? VolitionRX Ltd was founded in 2010 with headquarters in Austin, Texas. It is a multinational life science company specializing in the discovery of cancer and other disease markers. The company's mission is to improve the quality of life for millions of people worldwide through the development of pain diagnostic systems. History VolitionRX began as a collaboration between scientists Professor Avraham Rasooly from the University of California and Professor David Kroll from North Carolina State University. The two professors were searching for a more effective diagnostic method for cancer and eventually co-founded VolitionRX in 2010. Initially, the company focused on developing diagnostic tests for stomach and colorectal cancer. Business model VolitionRX is a research-based company that specializes in the development of diagnostic and testing systems for cancer. The company works closely with leading cancer experts and scientific institutions to achieve groundbreaking research results. The goal is to develop innovative diagnostic methods that enable doctors to detect cancer faster and more effectively. Divisions VolitionRX is divided into three main areas: diagnostic tests, research and development, and partner and customer relations. Diagnostic tests VolitionRX offers a variety of diagnostic tests for cancer and other diseases. The tests are based on nucleosomics technology, which allows for analysis of cellular DNA. VolitionRX has developed various tests for colorectal cancer, lung cancer, pancreatic cancer, and other types of cancer, and is working on new tests for other conditions. Research and development VolitionRX continuously invests in research and development of new diagnostic methods for cancer and other diseases. The company collaborates closely with leading scientific institutions and cancer experts to develop innovative solutions for cancer diagnostics. Partner and customer relations VolitionRX works with a range of partners to distribute its diagnostic tests worldwide. The company has partnerships with various diagnostic laboratories and medical institutions to make its tests available to a wider target audience. Products VolitionRX offers a variety of products for the diagnosis of cancer and other diseases. These include: 1. NuQ blood tests for the diagnosis of colorectal cancer and other types of cancer. 2. Nucleosomics technology for analysis of cellular DNA for early cancer detection. 3. Software for data analysis from medical tests. Future prospects VolitionRX aims to further improve its technology for cancer diagnosis in order to save lives and improve the quality of life for people worldwide. The company's future prospects are promising as the demand for fast and effective cancer diagnostic methods continues to increase due to the rising number of cancer cases worldwide. VolitionRX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about VolitionRX stock

Operating Income to Assets Ratio (EBIT/Assets) of VolitionRX is -287.52 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of VolitionRX changed from -128.76 % to -287.52 %, representing a 123.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) VolitionRX since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s VolitionRX with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — VolitionRX

All Key Metrics — VolitionRX